CGRP (rat)Cat. No. 1161 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: Calcitonin Gene-Related Peptide (rat) |
Biological Activity
Endogenous neuropeptide; potent vasodilator which also exerts cardiovascular, pro-inflammatory and metabolic effects.Technical Data
M.Wt:(Modifications: Disulfide bridge between 2 - 7, Phe-37 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
References
Morris et al (1984) Isolation and characterization of human calcitonin gene-related peptide. Nature 308 746. PMID: 6609312.
Brain et al (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313 54. PMID: 3917554.
Poyner (1995) Pharmacology of receptors for calcitonin gene-related peptide and amylin. TiPS 16 424. PMID: 8578616.
Nakamura et al (1998) Calcitonin gene-related peptide as a GH secretagogue in human and rat pituitary somatotrophs. Brain Res. 807 203. PMID: 9757038.
Salim et al (1998) Calcitonin gene-related peptide potentiates nicotinic acetylcholine receptor-operated slow Ca2+ mobilization at mouse muscle endplates. Br.J.Pharmacol. 125 277. PMID: 9786499.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: CGRP (rat), supplier, Potent, vasodilator, CGRP, Receptors, calcitonin-gene, related, peptide, AMY1, AMY2, AMY3, agonists
Quick Order
Find multiple products by catalog number
New Products in this Area
Oxytocin analog
ML 221Apelin receptor (APJ) antagonist
Q94 hydrochlorideNegative allosteric modulator at PAR1 receptor
FSLLRY-NH2PAR2 peptide antagonist
SB 611812Urotensin-II (UT) antagonist; attenuates cardiac dysfunction
TC-MCH 7cSelective melanin-concentrating hormone receptor 1 (MCH1R) antagonist
CYM 9484Potent NPY Y2 receptor antagonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.





